Back to Search
Start Over
Landscape and Regulatory Perspective on Oncology Drugs in Pregnancy.
- Source :
-
Journal of Clinical Pharmacology . Jun2023 Supplement 1, Vol. 63, pS170-S175. 6p. - Publication Year :
- 2023
-
Abstract
- Cancers affecting pregnant women include breast cancer, melanoma, thyroid cancer, cervical cancer, lymphomas, and leukemias. The medical management of cancer during pregnancy with molecularly targeted oncology drugs remains quite challenging, with knowledge gaps about the drugs' safety and efficacy due to exclusion of pregnant women from cancer clinical trials, discontinuation of individuals who become pregnant during clinical trials, and limited information on appropriate dosing of molecularly targeted oncology drugs during pregnancy. Physiological changes occur during pregnancy and may result in alterations in the absorption, distribution, metabolism, and excretion of drugs used in pregnant women. Physiologically based pharmacokinetic modeling that incorporates physiological changes induced by both the cancer disease state and pregnancy has the potential to inform dosing of molecularly targeted oncology drugs for pregnant women, improve our understanding of the pharmacokinetic changes associated with pregnancy in patients with cancer, facilitate the design of potential studies of molecularly targeted oncology drugs in pregnant women to support dosing recommendations, and provide modelāinformed pharmacokinetic data to support regulatory decision making. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00912700
- Volume :
- 63
- Database :
- Academic Search Index
- Journal :
- Journal of Clinical Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 164352421
- Full Text :
- https://doi.org/10.1002/jcph.2224